Best Viral Vector CDMOs in Europe

Last updated: 2026-10-22 · updated as new inspection, certificate, and trial data enters the platform

← All Viral Vector CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs tracked

Fully scored

With FDA records

FDA inspections

170

EMA/MHRA GMP certs

Warning letters

For European-manufactured viral vector programs, Takeda, AGC Biologics, and Oxford Biomedica lead CDMO Signal's ranking of viral vector CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 59 scored viral vector CDMOs to 5 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Viral vector CDMOs manufacture the three GMP-relevant vector platforms used in modern gene therapy and gene-modified cell therapy: adeno-associated virus (AAV), lentivirus, and adenovirus. Each platform has distinct process, containment, and analytics requirements, and CDMOs typically specialize in one or two platforms rather than all three. Platform is the first shortlist filter in any viral vector procurement decision.

This ranking aggregates every CDMO tracked as a viral vector manufacturer across the three platforms. For platform-specific rankings with process-critical detail (BSL-2 containment for lentivirus, full/empty capsid analytics for AAV, high-titre transient expression for adenovirus), use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors integrating vector supply with downstream cell processing (CAR-T, gene-modified HSC), the <a href="/modality/cell-and-gene-therapy">cell & gene therapy view</a> extends this list with cell therapy CDMOs.

FDA inspection outcomes across these CDMOs: 11 NAI (no action), 22 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (42), Denmark (35), United States (29), Germany (21), Italy (13).

Last updated 2026-10-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	TK Takeda Boston, MA · Zurich, CH	81.9	99.6	4 insp · 18 GMP	—	100 programs
2	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	78.6	100.0	2 insp · 23 GMP	Available	2 programs
3	OX Oxford Biomedica Oxford, United Kingdom	76.2	100.0	0 insp · 13 GMP	Available	7 programs
4	Lonza Basel, Switzerland	76.0	95.7	2 insp · 8 GMP	—	1 programs
5	RT ReiThera Rome, IT	71.1	100.0	0 insp · 4 GMP	—	1 programs
6	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	90.9	98.3	8 insp · 11 GMP	Limited	0 programs
7	RP ReciBioPharm Keele, UK · Sodertalje, SE	88.0	100.0	0 insp · 3 GMP	—	0 programs
8	FD FUJIFILM Diosynth Biotechnologies Research Triangle, NC · Holly Springs, NC · Hillerod, DK	84.8	100.0	0 insp · 23 GMP	Expanding	0 programs
9	BR BioReliance (Merck) Glasgow, UK · Rockville, MD	80.2	97.1	4 insp · 8 GMP	—	0 programs
10	SK SK pharmteco Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.	79.5	100.0	—	Available	0 programs
11	AA Ascend Advanced Therapies London, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
12	NG NecstGen Leiden, NL	78.1	100.0	0 insp · 1 GMP	—	0 programs
13	ET Exothera Jumet, BE	78.1	100.0	0 insp · 4 GMP	—	0 programs
14	PG ProBioGen Berlin, DE	78.1	100.0	0 insp · 4 GMP	—	0 programs
15	CE Celonic Basel, Switzerland	78.1	100.0	0 insp · 1 GMP	—	0 programs
16	XP eXmoor Pharma Bristol, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
17	AD Advent Bioservices London, United Kingdom	78.1	100.0	0 insp · 2 GMP	—	0 programs
18	BV Biovian Turku, Finland	78.0	99.8	1 insp · 4 GMP	—	0 programs
19	VG Viralgen Vector Core San Sebastián, Spain	76.8	100.0	0 insp · 4 GMP	Available	0 programs
20	CG Cytiva (Mfg Services) Marlborough, MA · Uppsala, SE	74.0	—	—	—	0 programs
21	Catalent Bagsværd, Denmark (operating under Novo Holdings)	73.1	74.9	12 insp · 37 GMP	—	0 programs
22	CA Catalent (Novo Holdings) Harmans, MD · Gosselies, BE	73.1	74.9	1 insp · 0 GMP	Available	0 programs
23	LZ Lonza Biologics Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH	73.0	95.7	1 insp · 0 GMP	Limited	0 programs
24	RA Recipharm Advanced Bio Stockholm, Sweden	63.0	—	—	—	0 programs
25	AB Asklepios BioPharmaceutical (AskBio) Research Triangle, NC · San Sebastian, ES	61.8	—	—	—	10 programs
26	CP Cell and Gene Therapy Catapult Stevenage, United Kingdom	59.0	—	—	—	0 programs
27	AM Anemocyte Gerenzano, Italy	59.0	—	—	—	0 programs
28	CV CEVEC Pharmaceuticals Cologne, Germany	56.5	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Viral Vector CDMO

Vector platform match

First shortlist filter for any viral vector program is platform. AAV for in vivo systemic, lentiviral for ex vivo cell engineering, adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within.

Facility-level regulatory record on the platform

A CDMO's strong FDA record on AAV does not automatically de-risk their lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use, not the CDMO's aggregate score.

Analytics maturity per vector

Full/empty capsid separation for AAV, RCL testing for lentivirus, particle-to-infectivity ratio for adenovirus — each platform has non-negotiable release-testing requirements. A CDMO's qualified, validated assay panel for the specific vector is the single most under-appreciated cost driver in viral vector programs.

Capacity match to phase and dose

AAV early clinical runs at 50-200L, commercial at 1,000-2,000L single batch; lentiviral commercial supply is a narrower field with per-patient-dose economics. Confirm the CDMO's capacity headroom at your target phase before shortlisting — capacity constraints appear late and derail commercial launches.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

Viral Vector CDMOs — Frequently Asked Questions

Who are the top Viral Vector CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Viral Vector CDMOs include Takeda, AGC Biologics, Oxford Biomedica. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Viral Vector CDMOs have FDA inspection records?

CDMO Signal tracks 9 Viral Vector CDMOs with FDA inspection records and 170 EMA/MHRA GMP certificates across the group.

What should I look for in a viral vector CDMO?

Match the vector platform first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, vector-specific analytics maturity, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific technical detail worth reading before finalizing a shortlist.

How many viral vector CDMOs does CDMO Signal track?

65+ CDMOs are tracked across the three GMP viral vector platforms — the union of AAV, lentiviral, and adenoviral manufacturers, deduplicated. Each is scored independently on the standard four-pillar Signal Score composite.

How is viral vector manufacturing different from mAb or recombinant protein biologics?

Viral vector manufacturing shares the mammalian cell culture upstream backbone with biologics but diverges sharply on downstream. Viral vector downstream requires enveloped/non-enveloped virus purification (chromatography, tangential flow filtration, ultracentrifugation) rather than protein A affinity capture. Analytics differ fundamentally — infectious titer and capsid analytics for viral vectors vs product-related impurities for biologics. Regulatory paths also differ: viral vectors carry additional biosafety review (RCL for lentivirus, adventitious agents for all platforms) beyond standard biologics.

Compare side-by-side

See two CDMOs' scoring, inspection history, and clinical footprint next to each other.

Open comparison →

Run a sourcing search

Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.

Search for a CDMO →

Save this Viral Vector shortlist

Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.

Related modalities

AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Adenoviral Vector CDMOs Cell Therapy CDMOs Gene Therapy CDMOs Cell & Gene Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy